The U.S. FDA is publicly recruiting members for its Tobacco Products Scientific Advisory Committee, with nominations accepted from both individuals and organizations

Jul.31.2025
The U.S. FDA is publicly recruiting members for its Tobacco Products Scientific Advisory Committee, with nominations accepted from both individuals and organizations
The U.S. FDA is soliciting voting members for the Tobacco Products Scientific Advisory Committee, with the nomination deadline set for August 25, 2025. This recruitment aims to fill five vacancies, including experts in the fields of oncology, pulmonology, cardiology, and others, as well as one representative from the general public and one from government employees. Selected members will serve a term of up to four years, beginning on February 1, 2026.

Key points:

·Member Recruitment: The FDA is openly soliciting members for the Tobacco Products Scientific Advisory Committee, covering experts from various medical and scientific fields. 

·Nomination Deadline: The deadline for nominations is August 25, 2025, and can be submitted electronically or by mail. 

·Term Arrangement: New members will serve for a maximum of four years, starting from February 1, 2026. 

·Committee Responsibilities: TPSAC is responsible for reviewing the safety, dependence, and health issues of tobacco products, providing professional advice to the FDA.

 


 

According to an FDA announcement on July 30th, the FDA is seeking nominations for voting members to join the Tobacco Products Scientific Advisory Committee (TPSAC) by August 25, 2025. Individuals can self-nominate or be nominated by any interested person or organization.

 

Specifically, the TPSAC is looking for five vacant members, who should be doctors, dentists, scientists, or healthcare professionals specializing in oncology, pulmonology, cardiology, toxicology, pharmacology, engineering, or other related fields. Among these five vacancies are one for a representative of the general public and one for a federal, state, or local government employee. The selected members will be invited to serve for a maximum of four years, with their term beginning on February 1, 2026, after the current members' terms end.

 

All nominations should be submitted electronically through the FDA Advisory Nomination Portal, or by email to the committee's oversight and management staff. Nominations received after August 25, 2025 will be considered for future committee vacancies.

 

The Tobacco Products Scientific Advisory Committee (TPSAC) advises the FDA on matters related to tobacco product regulation, such as applications for modified risk tobacco products submitted by manufacturers. This committee reviews and evaluates the safety, addictiveness, and health issues related to tobacco products, and provides appropriate advice, information, and recommendations to the FDA Commissioner.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

JTI Korea Rebrands Ploom Sticks to “EVO,” Launches 8 Variants
JTI Korea Rebrands Ploom Sticks to “EVO,” Launches 8 Variants
JTI Korea said it will rebrand the dedicated stick line for its heated tobacco device Ploom, changing the name from “Mebius for Ploom” to “EVO.”
Mar.10 by 2FIRSTS.ai
The UK government plans to expand the scope of its e-cigarette ban to include playgrounds, off-campus areas, and areas outside hospitals.
The UK government plans to expand the scope of its e-cigarette ban to include playgrounds, off-campus areas, and areas outside hospitals.
Government plans would ban vaping in cars carrying children and restrict smoking, vaping and heated tobacco in settings including playgrounds and outside schools across England, subject to a 12-week public consultation. The proposals also say indoor spaces where smoking is already banned would become vape- and heated-tobacco-free, and areas outside hospitals would be included.
Feb.13 by 2FIRSTS.ai
Philip Morris and BAT’s Nicoventures Win EPO Appeal to Revoke VMR Vape Patent
Philip Morris and BAT’s Nicoventures Win EPO Appeal to Revoke VMR Vape Patent
The EPO Technical Board of Appeal 3.2.02 (T 1319/24) revoked VMR Products LLC’s EP3613453 “VAPORIZER” patent after finding that a 2012 YouTube video of the Innokin iTaste VV (D3) disclosed the claimed electrical contact arrangement. Opponents Nicoventures Trading Ltd (BAT subsidiary) and Philip Morris Products S.A. prevailed.
BATPMI
Feb.17
NYC makers turn discarded disposable vapes into “Vape Synth” mini digital instruments
NYC makers turn discarded disposable vapes into “Vape Synth” mini digital instruments
The report says disposable vapes are sold at more than 11 million units per month and often end up in landfills after flavored nicotine juice runs out, along with lithium-ion batteries, microcontrollers, and LEDs, increasing the risk of waste fires. A New York City maker trio known as Paper Bag Team has built “Vape Synth” by cracking open spent Elf Bar cartridges—specifically the EB BC5000—and hacking them into tiny digital instruments.
Feb.12 by 2FIRSTS.ai
2Firsts Flash|PMI Reports 2025 Results as Smoke-Free Products Account for 41.5% of Net Revenues
2Firsts Flash|PMI Reports 2025 Results as Smoke-Free Products Account for 41.5% of Net Revenues
Philip Morris International reported full-year 2025 results on February 6, with smoke-free products accounting for 41.5% of adjusted net revenues, up from 38.7% a year earlier. Total net revenues rose 7.3% to $40.65 billion, while shipment volumes increased 1.4%, widening the gap between revenue and volume growth. Cigarette shipments declined as smoke-free volumes rose 12.8%, driven by heated tobacco, oral nicotine and e-vapor products. Results were released alongside a 9:00 a.m. EST webcast.
Feb.06
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24